Cited 14 times in
Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민필기 | - |
dc.contributor.author | 이상학 | - |
dc.date.accessioned | 2015-04-24T16:35:15Z | - |
dc.date.available | 2015-04-24T16:35:15Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0954-6928 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103794 | - |
dc.description.abstract | BACKGROUND: Aggressive platelet inhibition is crucial to reduce myocardial injury and early cardiac events after coronary intervention. As compared with the conventional 300-mg dose, pretreatment with a 600-mg loading dose of clopidogrel significantly reduced periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). We investigated that the advantage of the 600-mg dose in inhibiting platelet aggregation more rapidly than the 300-mg dose may actually have special value for acute ST-segment elevation MI patients. METHODS: A total of 171 patients with ST-segment elevation MI underwent primary PCI. A 600-mg (n=73) or 300-mg (n=98) loading regimen of clopidogrel was given before the procedure. We did a follow-up of all patients clinically for 30 days after coronary intervention. the primary endpoint was the 30-day occurrence of death, MI, urgent revascularization, or stroke. RESULTS: the primary endpoint occurred in 1.4% (1 of 73) of patients in the high dose versus 11.2% (11 of 98) of those in the conventional loading dose group (P=0.013). Death, recurrent MI, urgent revascularization, and stroke were lower in patients treated with the high dose of clopidogrel compared with conventional dose. Safety endpoints were similar in the two groups. CONCLUSION: Pretreatment with a 600-mg loading dose of clopidogrel before the procedure is safe and, as compared with the conventional 300-mg dose, significantly reduces recurrent MI and urgent revascularization in patients with primary PCI. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CORONARY ARTERY DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angioplasty, Balloon, Coronary/adverse effects | - |
dc.subject.MESH | Angioplasty, Balloon, Coronary/instrumentation* | - |
dc.subject.MESH | Angioplasty, Balloon, Coronary/mortality | - |
dc.subject.MESH | Coronary Artery Disease/drug therapy* | - |
dc.subject.MESH | Coronary Artery Disease/mortality | - |
dc.subject.MESH | Coronary Artery Disease/therapy* | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction/etiology | - |
dc.subject.MESH | Myocardial Infarction/prevention & control | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/administration & dosage* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Stents* | - |
dc.subject.MESH | Stroke/etiology | - |
dc.subject.MESH | Stroke/prevention & control | - |
dc.subject.MESH | Ticlopidine/administration & dosage | - |
dc.subject.MESH | Ticlopidine/analogs & derivatives* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jae-Hun Jung | - |
dc.contributor.googleauthor | Pil-Ki Min | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.contributor.googleauthor | Chong Won Sung | - |
dc.contributor.googleauthor | Seonghoon Choi | - |
dc.contributor.googleauthor | Jung Rae Cho | - |
dc.contributor.googleauthor | Namho Lee | - |
dc.contributor.googleauthor | Ki Hyun Byun | - |
dc.identifier.doi | 10.1097/MCA.0b013e3283262de2 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01412 | - |
dc.contributor.localId | A02705 | - |
dc.contributor.localId | A03714 | - |
dc.contributor.localId | A03903 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J00649 | - |
dc.identifier.eissn | 1473-5830 | - |
dc.identifier.pmid | 19301464 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00019501-200903000-00011&LSLINK=80&D=ovft | - |
dc.subject.keyword | clopidogrel | - |
dc.subject.keyword | myocardial infarction | - |
dc.subject.keyword | percutaneous transluminal | - |
dc.subject.keyword | coronary angioplasty | - |
dc.contributor.alternativeName | Min, Pil Ki | - |
dc.contributor.alternativeName | Lee, Sang Hak | - |
dc.contributor.affiliatedAuthor | Min, Pil Ki | - |
dc.contributor.affiliatedAuthor | Lee, Snag Hak | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 150 | - |
dc.citation.endPage | 154 | - |
dc.identifier.bibliographicCitation | CORONARY ARTERY DISEASE, Vol.20(2) : 150-154, 2009 | - |
dc.identifier.rimsid | 36696 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.